Talphera, Inc. reported a net loss of $14.3 million for the fiscal year ending December 31, 2025, compared to a loss of $13.0 million in 2024. The company's total revenue for 2025 was $28,000, a modest increase from zero revenue in the previous year. As of December 31, 2025, Talphera had cash, cash equivalents, and short-term investments totaling $20.4 million, up from $8.9 million at the end of 2024. The increase in cash reserves was primarily due to successful capital raises through private placements, which provided approximately $22.7 million in financing during the year.
The company has focused its resources on the development of its lead product candidate, Niyad, a regional anticoagulant for use in continuous renal replacement therapy (CRRT). Talphera's acquisition of Lowell Therapeutics in January 2022, which included Niyad, has been a significant strategic move, although the company has faced challenges in clinical trial enrollment and regulatory approvals. The NEPHRO CRRT study, which is pivotal for Niyad's approval, has experienced slower than expected patient enrollment, impacting timelines for potential commercialization.
Operationally, Talphera's employee headcount stood at 12 full-time employees as of December 31, 2025. The company has been actively managing its expenses, with research and development costs decreasing to $6.0 million in 2025 from $6.7 million in 2024. Selling, general, and administrative expenses also fell to $7.5 million from $8.5 million in the prior year, reflecting cost-cutting measures including reductions in consulting fees and board compensation.
Looking ahead, Talphera anticipates needing additional capital to fund its operations and development activities, particularly as it continues to incur losses. The company has indicated that it may seek further financing through equity offerings or strategic partnerships. Additionally, Talphera is under pressure to regain compliance with Nasdaq's minimum bid price rule, having received a notice in March 2026 regarding its stock price falling below the required threshold. The company is exploring options to address this compliance issue, which could include a reverse stock split. Overall, Talphera's future performance will depend heavily on the successful development and commercialization of Niyad and its ability to secure necessary funding.
About TALPHERA, INC.
Talphera, Inc. is a specialty pharmaceutical company developing innovative therapies for use in medically supervised settings. Its portfolio includes nafamostat-based product candidates for anticoagulation, antiviral, and inflammatory indications, targeting hospital and critical care markets. The company focuses on obtaining regulatory approvals, advancing clinical trials, and commercializing therapies that address unmet medical needs, leveraging proprietary formulations, patents, and strategic partnerships.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.